1. General characteristics (Time Frame - 10 years): To describe the general characteristics of advanced or metastatic stage patients in Austria (Stage III A-C and IV A-B NSCLC, limited disease (LD) and extensive disease (ED) SCLC)
2. Molecular testing (Time Frame - 10 years): To describe molecular testing in patients with advanced or metastatic lung cancer
number of patients with molecular testing
methods for molecular testing
number of patients with PD-L1 testing
PD-L1 % range per disease stage
PD-L1 test antibody used
number of genes tested
number of patients with at least one mutation identified
number of patients with at least one druggable target identified
3. Characterize subgroups (Time Frame - 10 years): To describe and characterize subgroups
Number of patients with NSCLC
Number of patients that receive immune-checkpoint inhibitors
Number of patients with targetable/druggable mutations
4. Treatment duration (Time Frame - 10 years): To describe duration of treatment
5. Treatment frequency (Time Frame - 10 years): To describe frequency of treatment
6. Degree of treatment response (Time Frame - 10 years): To describe degree of treatment response in %
7. Treatment sequence (Time Frame - 10 years): To describe sequence of use of various treatments
8. Outcome OS (Time Frame - 10 years): To describe patient outcome by means of overall survival (OS) in %
9. Outcome PFS (Time Frame - 10 years): To describe patient outcome by means of progression free survival (PFS) in %
10. Toxicity of treatment (Time Frame - 10 years): To describe number of patients with toxicity of treatment with a focus on immune related adverse events
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Lung Cancer Registry"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!